Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327   pISSN 1738-1088

Cited by CrossRef (5)

  1. Zack Blumenfeld, Kallol Bera, Eero Castrén, Henry A. Lester. Antidepressants enter cells, organelles, and membranes. Neuropsychopharmacol. 2024;49:246
    https://doi.org/10.1038/s41386-023-01725-x
  2. Vivian W.L. Tsang, Brendan Tao, Shannon Dames, Zach Walsh, Pam Kryskow. Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots To Thrive ketamine-assisted therapy program: a retrospective chart review. Therapeutic Advances in Psychopharmacology 2023;13:204512532311715
    https://doi.org/10.1177/20451253231171512
  3. John H. Krystal, Alfred P. Kaye, Sarah Jefferson, Matthew J. Girgenti, Samuel T. Wilkinson, Gerard Sanacora, Irina Esterlis. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proc. Natl. Acad. Sci. U.S.A. 2023;120
    https://doi.org/10.1073/pnas.2305772120
  4. Michael D. Kritzer, Chi-Un Pae, Prakash S. Masand. Key considerations for the use of ketamine and esketamine for the treatment of depression: focusing on administration, safety, and tolerability. Expert Opinion on Drug Safety 2022;21:725
    https://doi.org/10.1080/14740338.2022.2069749
  5. M. Fornaro, C.I. Cattaneo, D. De Berardis, F.V. Ressico, G. Martinotti, E. Vieta. Antidepressant discontinuation syndrome: A state-of-the-art clinical review. European Neuropsychopharmacology 2023;66:1
    https://doi.org/10.1016/j.euroneuro.2022.10.005